Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Shareholder-Value

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 16, 2022 11:45am

140 Views

Post# 35175884

RE:Shareholder-Value

"In soccer you would say it's 0:2 against Ceapro.
(Beta Glucan + Energy Drink)"

Realistically development stage assets take a long and winding road through trial-and-error. It can take 10 years to develop them ore more. That they make it to success in a straight line is largely a fantasy. Most early-stage R&D fails. CZO's oat beta glucan was set aside for now because CZO has more compelling immediate opportunity. It could still be successful in a liquid form instead of a pill based on another trial. It could be picked up later.

Gilles joined CZO because of avenanthramide. A clinical trial is now before Health Canada for the final green light. That is the priority. The energy drink was a prototype based on oat beta glucan. It has been valuable in developing PGX-YBG, and PGX-Alginate which are believed to meet the needs of industry based on discussions with industry with the prototype. PGX-YBG and PGX-Alginate have interesting properties. Getting things right the first time is very rare. These second generation carriers(PGX-YBG, PGX-Alginate, PGX-YBG-Alginate) have now been tested in a bioavailability study and justify scale-up.

"The 3rd quarter results disappointed shareholders so much that looking back at the 1st half of the year didn't help either."

14% growth for the first nine months is well in line with the historic growth of the company. Any given quarter to two can be lumpy based on when orders fall. The deal signed with Symrise this year may lead to 'accelerating' sales it is noted based on certain exclusivities, etc.

See the source image